23
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Gut microbial diversity is associated with lower arterial stiffness in women

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aims

          The gut microbiome influences metabolic syndrome (MetS) and inflammation and is therapeutically modifiable. Arterial stiffness is poorly correlated with most traditional risk factors. Our aim was to examine whether gut microbial composition is associated with arterial stiffness.

          Methods and results

          We assessed the correlation between carotid-femoral pulse wave velocity (PWV), a measure of arterial stiffness, and gut microbiome composition in 617 middle-aged women from the TwinsUK cohort with concurrent serum metabolomics data. Pulse wave velocity was negatively correlated with gut microbiome alpha diversity (Shannon index, Beta(SE)= −0.25(0.07), P = 1 × 10 −4) after adjustment for covariates. We identified seven operational taxonomic units associated with PWV after adjusting for covariates and multiple testing—two belonging to the Ruminococcaceae family. Associations between microbe abundances, microbe diversity, and PWV remained significant after adjustment for levels of gut-derived metabolites (indolepropionate, trimethylamine oxide, and phenylacetylglutamine). We linearly combined the PWV-associated gut microbiome-derived variables and found that microbiome factors explained 8.3% (95% confidence interval 4.3–12.4%) of the variance in PWV. A formal mediation analysis revealed that only a small proportion (5.51%) of the total effect of the gut microbiome on PWV was mediated by insulin resistance and visceral fat, c-reactive protein, and cardiovascular risk factors after adjusting for age, body mass index, and mean arterial pressure.

          Conclusions

          Gut microbiome diversity is inversely associated with arterial stiffness in women. The effect of gut microbiome composition on PWV is only minimally mediated by MetS. This first human observation linking the gut microbiome to arterial stiffness suggests that targeting the microbiome may be a way to treat arterial ageing.

          Related collections

          Most cited references39

          • Record: found
          • Abstract: found
          • Article: not found

          The role of the gut microbiome in systemic inflammatory disease

          The role of the gut microbiome in models of inflammatory and autoimmune disease is now well characterized. Renewed interest in the human microbiome and its metabolites, as well as notable advances in host mucosal immunology, has opened multiple avenues of research to potentially modulate inflammatory responses. The complexity and interdependence of these diet-microbe-metabolite-host interactions are rapidly being unraveled. Importantly, most of the progress in the field comes from new knowledge about the functional properties of these microorganisms in physiology and their effect in mucosal immunity and distal inflammation. This review summarizes the preclinical and clinical evidence on how dietary, probiotic, prebiotic, and microbiome based therapeutics affect our understanding of wellness and disease, particularly in autoimmunity.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found
            Is Open Access

            Diabetes, obesity and gut microbiota.

            The gut microbiota composition has been associated with several hallmarks of metabolic syndrome (e.g., obesity, type 2 diabetes, cardiovascular diseases, and non-alcoholic steatohepatitis). Growing evidence suggests that gut microbes contribute to the onset of the low-grade inflammation characterising these metabolic disorders via mechanisms associated with gut barrier dysfunctions. Recently, enteroendocrine cells and the endocannabinoid system have been shown to control gut permeability and metabolic endotoxaemia. Moreover, targeted nutritional interventions using non-digestible carbohydrates with prebiotic properties have shown promising results in pre-clinical studies in this context, although human intervention studies warrant further investigations. Thus, in this review, we discuss putative mechanisms linking gut microbiota and type 2 diabetes. These data underline the advantage of investigating and changing the gut microbiota as a therapeutic target in the context of obesity and type 2 diabetes. Copyright © 2013 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites

              Amalio Telenti, Craig Venter and colleagues report common, low-frequency and rare variants associated with blood metabolite levels using whole-genome sequencing and comprehensive metabolite profiling in 1,960 individuals. They identify 246 metabolites whose levels are associated with genetic variation at 101 loci.
                Bookmark

                Author and article information

                Journal
                Eur Heart J
                Eur. Heart J
                eurheartj
                European Heart Journal
                Oxford University Press
                0195-668X
                1522-9645
                01 July 2018
                09 May 2018
                09 May 2018
                : 39
                : 25 , Focus Issue on Prevention
                : 2390-2397
                Affiliations
                [1 ]Department of Twin Research and Genetic Epidemiology, King’s College London, St Thomas' Hospital, London, UK
                [2 ]Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Fuxing Street, Guishan Dist., Taoyuan City, Taiwan
                [3 ]Department of Clinical Pharmacology, British Heart Foundation Centre, King’s College London, St Thomas' Hospital, London, UK
                [4 ]NIHR Biomedical Research Centre at Guy’s and St Thomas’ Foundation Trust, St Thomas’ Hospital, London, UK
                [5 ]Metabolon Inc., Research Triangle Park, NC, USA
                [6 ]School of Medicine, Nottingham City Hospital, Hucknall Road, Nottingham, UK
                [7 ]NIHR Nottingham Biomedical Research Centre, Queen's Medical Centre, Derby Rd, Nottingham, UK
                Author notes
                Corresponding author. Tel: +44 (0)115 823 1954, Fax: +44(0) 115 823 1757, Email: Ana.Valdes@ 123456nottingham.ac.uk
                Article
                ehy226
                10.1093/eurheartj/ehy226
                6030944
                29750272
                d980233c-bc2b-4701-9949-b41d14dab0c2
                © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Cardiology.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 06 October 2017
                : 06 December 2017
                : 06 April 2018
                Page count
                Pages: 9
                Funding
                Funded by: BHF 10.13039/501100000274
                Award ID: SP/12/4/29573
                Funded by: MRC AIM HY
                Award ID: MR/M016560/1
                Funded by: HEALS
                Award ID: 603946
                Funded by: European Union’s Seventh Framework Programme
                Funded by: National Institute of Health
                Award ID: RO1 DK093595
                Award ID: DP2 OD007444
                Funded by: Wellcome Trust 10.13039/100004440
                Funded by: Seventh Framework Programme 10.13039/100011102
                Award ID: FP7/2007-2013
                Funded by: National Institute for Health Research 10.13039/501100000272
                Funded by: Clinical Research Facility at Guy’s
                Funded by: Thomas’ NHS Foundation Trust and King’s College London
                Funded by: Chronic Disease Research
                Funded by: Denise Coates Foundation
                Categories
                Clinical Research
                Obesity and Metabolic Syndrome
                Editor's Choice

                Cardiovascular Medicine
                gut microbiome diversity,arterial stiffness,microbial metabolites,indolepropionate,metabolic syndrome,inflammation

                Comments

                Comment on this article